Blue MAP Pharmachem

Blue MAP Pharmachem is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2006, the company is headquartered at 5th Floor, 513/514, Agarwal B2B Centre, Kanchpada Road, Off Link Road, Malad West, Mumbai, Maharashtra, 400064, India. The business operates as a sole proprietorship under the legal name Vikram Ashok Panjwani. It is registered with the Directorate General of Foreign Trade (DGFT) under the Importer Exporter Code (IEC) number RA000709. The company holds a Goods and Services Tax (GST) registration number 27APRPP3311H1ZQ, indicating its active status as of July 1, 2017. While specific revenue figures are not publicly disclosed, Blue MAP Pharmachem has demonstrated a consistent export performance, with a total export value of $1.2 million USD across 43 shipments from 2022 to 2026. The company's product portfolio is concentrated, with its top two products—Artesunate and Chondroitin—accounting for 100% of its exports. The workforce comprises a dedicated team, though exact employee numbers are not specified in the available sources.

Blue MAP Pharmachem's manufacturing operations are based in India, with facilities located in Mumbai, Maharashtra. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding manufacturing capacities and certifications are not publicly available. The company's focus on finished formulations indicates a commitment to quality and compliance with international standards, catering to various therapeutic categories.

The available sources do not provide detailed information about the key leadership team at Blue MAP Pharmachem. The company's legal name is Vikram Ashok Panjwani, suggesting that Mr. Panjwani may hold a significant leadership role. However, without explicit confirmation, it is not possible to accurately identify the CEO, CFO, or other key executives.

Blue MAP Pharmachem's export activities primarily focus on markets in Africa, with notable shipments to Ghana. The company's product portfolio includes Artesunate and Chondroitin, both of which are used in the treatment of malaria and related conditions. While specific regulatory approvals for the U.S., EU, UK, Australia, and Japan are not detailed in the available sources, the company's export activities suggest compliance with international standards. The absence of explicit regulatory filings or approvals in these regions indicates that Blue MAP Pharmachem may not currently have market access in these countries.

Blue MAP Pharmachem has demonstrated a presence in emerging markets, particularly in Africa. The company's export data indicates shipments to Ghana, highlighting its engagement in the African pharmaceutical market. While specific information regarding WHO prequalification or other certifications enabling access to these markets is not available, the company's export activities suggest a focus on meeting international standards for pharmaceutical products.

Blue MAP Pharmachem's export strategy appears concentrated, with a significant focus on specific products and markets. The company's top two products—Artesunate and Chondroitin—account for 100% of its exports, indicating a high level of portfolio concentration. This concentration may expose the company to risks associated with market fluctuations and regulatory changes in its target markets. Diversifying its product portfolio and exploring additional markets could mitigate these risks and enhance the company's strategic position.

Specific information regarding Blue MAP Pharmachem's interactions with the U.S. Food and Drug Administration (FDA) is not available in the provided sources. The company's export data does not indicate shipments to the United States, suggesting that it may not currently have FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. Without explicit confirmation, it is not possible to assess the company's FDA status accurately.

The available sources do not provide information regarding Blue MAP Pharmachem's compliance with World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. The company's export activities, particularly in Africa, suggest a focus on meeting international standards; however, without explicit confirmation, it is not possible to assess the company's adherence to WHO or EU GMP standards.

Blue MAP Pharmachem operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's GST registration number 27APRPP3311H1ZQ indicates compliance with Indian tax regulations. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available. The company's export data suggests adherence to Indian regulatory standards; however, without explicit confirmation, it is not possible to assess the company's full compliance with CDSCO and state regulations.

The available sources do not provide information regarding any recent regulatory actions involving Blue MAP Pharmachem, such as FDA Form 483 observations, warning letters, or import alerts. The company's export data does not indicate any regulatory issues; however, without explicit confirmation, it is not possible to assess the company's regulatory history comprehensively.

Blue MAP Pharmachem operates in the competitive pharmaceutical export market, focusing on finished formulations like Artesunate and Chondroitin. While specific competitors in overlapping categories are not detailed in the available sources, the company's export data indicates a presence in markets such as Ghana. The absence of explicit information regarding market share comparisons and head-to-head analyses suggests that Blue MAP Pharmachem may face competition from both local and international pharmaceutical companies in its target markets.

Blue MAP Pharmachem's key differentiators include its specialization in finished pharmaceutical formulations and a concentrated product portfolio. The company's focus on products like Artesunate and Chondroitin positions it in the niche market of antimalarial and nutritional supplements. While specific competitive advantages are not detailed in the available sources, the company's export activities suggest a commitment to quality and compliance with international standards.

Blue MAP Pharmachem's current strategic direction appears focused on exporting finished pharmaceutical formulations, with a concentrated product portfolio. The company's export data indicates a presence in markets such as Ghana, suggesting a strategy targeting specific regions. The absence of explicit information regarding future outlooks, such as plans to expand into generics, specialty drugs, biosimilars, or contract development and manufacturing organizations (CDMO), indicates that the company's strategic direction may be evolving.

Blue MAP Pharmachem's export data indicates a consistent track record, with a total export value of $1.2 million USD across 43 shipments from 2022 to 2026. The company's product portfolio is concentrated, with its top two products—Artesunate and Chondroitin—accounting for 100% of its exports. The company's export activities suggest reliability in fulfilling orders; however, without explicit information regarding supplier relationships, it is not possible to assess the company's overall reliability indicators comprehensively.

Importers considering partnerships with Blue MAP Pharmachem should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations. Verification can be done through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Verify adherence to World Health Organization Good Manufacturing Practice (WHO-GMP) standards to ensure product quality and safety. This can be confirmed through the WHO's official website or by requesting certification details from the company.

• EU GMP Certification: Ensure compliance with European Union Good Manufacturing Practice (EU GMP) standards for products intended for the European market. Verification can be done through the European Medicines Agency (EMA) or by contacting the company directly.

• ISO Certification: Check for International Organization for Standardization (ISO) certifications related to quality management systems. These can be verified through the International Organization for Standardization's official website or by requesting certification details from the company.

Importers should undertake the following steps to verify Blue MAP Pharmachem's credentials and ensure a reliable partnership:

• Verify Regulatory Certifications: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO-GMP, EU GMP, and ISO standards.

• Assess Product Quality: Request product samples and review quality control documentation to ensure adherence to international standards.

• Evaluate Financial Stability: Review financial statements and credit reports to assess the company's financial health and reliability.

• Check References: Contact previous and current clients to gather